Lung Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Lung Cancer, including details on symptoms, smoking, genetics, treatment, causes.

Volume 4 (2007), Issue 9 (September)

1. Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides.
   Nanomedicine, 3(3): 173-83. [Abstract] [Full-text]
2. Usefulness of low-dose CT in the detection of pulmonary metastasis of gestational trophoblastic tumours.
   Clin Radiol, 62(10): 998-1003. [Abstract] [Full-text]
3. Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.
   BMC Cancer, 7: 150. [Abstract] [Full-text]
4. Radiation-enhanced vascular targeting of human lung cancers in mice with a monoclonal antibody that binds anionic phospholipids.
   Clin Cancer Res, 13(17): 5211-8. [Abstract] [Full-text]
5. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.
   Clin Cancer Res, 13(17): 5150-5. [Abstract] [Full-text]
6. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer.
   Clin Cancer Res, 13(17): 5076-81. [Abstract] [Full-text]
7. Rapid detection of epidermal growth factor receptor mutations in lung cancer by the SMart-Amplification Process.
   Clin Cancer Res, 13(17): 4974-83. [Abstract] [Full-text]
8. The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer.
   Cancer Lett, 256(1): 112-9. [Abstract] [Full-text]
9. Presentation of Garcin syndrome due to lung cancer.
   J Thorac Oncol, 2(9): 877-8. [Abstract] [Full-text]
10. Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    J Thorac Oncol, 2(9): 854-61. [Abstract] [Full-text]
11. Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis.
    J Thorac Oncol, 2(9): 845-53. [Abstract] [Full-text]
12. Sequential chemotherapy with combination irinotecan and cisplatin followed by docetaxel for treatment-naïve patients with advanced non-small cell lung cancer.
    J Thorac Oncol, 2(9): 838-44. [Abstract] [Full-text]
13. A prospective phase II study of induction carboplatin and vinorelbine followed by concomitant topotecan and accelerated radiotherapy (ART) in locally advanced non-small cell lung cancer (NSCLC).
    J Thorac Oncol, 2(9): 831-7. [Abstract] [Full-text]
14. Presentation and stage-specific outcomes of lifelong never-smokers with non-small cell lung cancer (NSCLC).
    J Thorac Oncol, 2(9): 827-30. [Abstract] [Full-text]
15. Beliefs among physicians in the diagnostic and therapeutic approach to non-small cell lung cancer.
    J Thorac Oncol, 2(9): 819-26. [Abstract] [Full-text]
16. A web site on lung cancer: who are the users and what are they looking for?
    J Thorac Oncol, 2(9): 813-8. [Abstract] [Full-text]
17. Risk factors for recurrence and unfavorable prognosis in patients with stage I non-small cell lung cancer and a tumor diameter of 20 mm or less.
    J Thorac Oncol, 2(9): 808-12. [Abstract] [Full-text]
18. HOXB2 as a novel prognostic indicator for stage I lung adenocarcinomas.
    J Thorac Oncol, 2(9): 802-7. [Abstract] [Full-text]
19. Neuronatin expression and its clinicopathological significance in pulmonary non-small cell carcinoma.
    J Thorac Oncol, 2(9): 796-801. [Abstract] [Full-text]
20. Definitive chemoradiation for the treatment of locally advanced non small-cell lung cancer.
    J Clin Oncol, 25(26): 4146-52. [Abstract] [Full-text]
21. Limited-stage small-cell lung cancer: the current status of combined-modality therapy.
    J Clin Oncol, 25(26): 4137-45. [Abstract] [Full-text]
22. Resection of malignant tumors invading the vena cava: perioperative complications and long-term follow-up.
    J Vasc Surg, 46(3): 533-40. [Abstract] [Full-text]
23. Parathyroid hormone-related protein varies with sex and androgen status in nonsmall cell lung cancer.
    Cancer, 110(6): 1313-20. [Abstract] [Full-text]
24. Epidermal growth factor ligand/receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer.
    Cancer, 110(6): 1321-8. [Abstract] [Full-text]
25. Homozygous deletion scanning of the lung cancer genome at a 100-kb resolution.
    Genes Chromosomes Cancer, 46(11): 1000-10. [Abstract] [Full-text]
26. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA).
    Br J Cancer, 97(6): 778-84. [Abstract] [Full-text]
27. Modulatory effects of heparin and short-length oligosaccharides of heparin on the metastasis and growth of LMD MDA-MB 231 breast cancer cells in vivo.
    Br J Cancer, 97(6): 761-8. [Abstract] [Full-text]
28. Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts.
    Br J Cancer, 97(6): 735-40. [Abstract] [Full-text]
29. IL-12 gene-modified bone marrow cell therapy suppresses the development of experimental metastatic prostate cancer.
    Cancer Gene Ther, 14(10): 819-27. [Abstract] [Full-text]
30. Development of human umbilical cord matrix stem cell-based gene therapy for experimental lung tumors.
    Cancer Gene Ther, 14(10): 828-35. [Abstract] [Full-text]
31. Emerging drugs for non-small-cell lung cancer.
    Expert Opin Emerg Drugs, 12(3): 449-60. [Abstract] [Full-text]
32. Interobserver agreement on what constitutes visceral pleural invasion by non-small cell lung carcinoma: an internet-based assessment of international current practices.
    Am J Clin Pathol, 128(4): 638-47. [Abstract] [Full-text]
33. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20.
    J Clin Oncol, 25(27): 4278-84. [Abstract] [Full-text]
34. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.
    J Clin Oncol, 25(27): 4270-7. [Abstract] [Full-text]
35. Lung cancer survival and functional polymorphisms in MBL2, an innate-immunity gene.
    J Natl Cancer Inst, 99(18): 1401-9. [Abstract] [Full-text]
36. Reducing healthy worker survivor bias by restricting date of hire in a cohort study of Vermont granite workers.
    Occup Environ Med, 64(10): 681-7. [Abstract] [Full-text]
37. Persistent pulmonary nodular ground-glass opacity at thin-section CT: histopathologic comparisons.
    Radiology, 245(1): 267-75. [Abstract] [Full-text]
38. Pecoma of the lung: a benign tumor with extensive 18F-2-deoxy-D-glucose uptake.
    Interact Cardiovasc Thorac Surg, 6(5): 676-8. [Abstract] [Full-text]
39. Video-assisted thoracoscopic lobectomy vs. conventional lobectomy via open thoracotomy in patients with clinical stage IA non-small cell lung carcinoma.
    Interact Cardiovasc Thorac Surg, 6(5): 614-7. [Abstract] [Full-text]
40. Imaging features of pulmonary Kaposi sarcoma-associated immune reconstitution syndrome.
    AJR Am J Roentgenol, 189(4): 956-65. [Abstract] [Full-text]
41. Computer-aided detection of solid lung nodules on follow-up MDCT screening: evaluation of detection, tracking, and reading time.
    AJR Am J Roentgenol, 189(4): 948-55. [Abstract] [Full-text]
42. Tumorigenic stem and progenitor cells: implications for the therapeutic index of anti-cancer agents.
    J Control Release, 122(3): 385-91. [Abstract] [Full-text]
43. Treating non-small-cell lung cancer first line with erlotinib monotherapy in elderly patients: discussion of a case series.
    Onkologie, 30(10): 515-8. [Abstract] [Full-text]
44. Lung cancer in never smokers--a different disease.
    Nat Rev Cancer, 7(10): 778-90. [Abstract] [Full-text]
45. Estimation of error in maximal intensity projection-based internal target volume of lung tumors: a simulation and comparison study using dynamic magnetic resonance imaging.
    Int J Radiat Oncol Biol Phys, 69(3): 895-902. [Abstract] [Full-text]
46. Implantation and stability of metallic fiducials within pulmonary lesions.
    Int J Radiat Oncol Biol Phys, 69(3): 777-85. [Abstract] [Full-text]
47. Phase I/II trial of sequential chemoradiotherapy using a novel hypoxic cell radiosensitizer, doranidazole (PR-350), in patients with locally advanced non-small-cell lung Cancer (WJTOG-0002).
    Int J Radiat Oncol Biol Phys, 69(3): 786-92. [Abstract] [Full-text]
48. Oncogene and tumor-suppressor gene products as serum biomarkers in occupational-derived lung cancer.
    Expert Rev Mol Diagn, 7(5): 555-68. [Abstract] [Full-text]
49. Prospective study of leukocyte count as a predictor of incident breast, colorectal, endometrial, and lung cancer and mortality in postmenopausal women.
    Arch Intern Med, 167(17): 1837-44. [Abstract] [Full-text]
50. Prognostic factors for survival of stage I nonsmall cell lung cancer patients : a population-based analysis of 19,702 stage I patients in the California Cancer Registry from 1989 to 2003.
    Cancer, 110(7): 1532-41. [Abstract] [Full-text]
51. Expression of TGFbeta type-II receptor in association with markers of proliferation and apoptosis in premalignant lung lesions.
    Cancer, 110(7): 1527-31. [Abstract] [Full-text]
52. Hypermethylation of the Dal-1 gene in lung adenocarcinomas induced by N-nitrosobis(2-hydroxypropyl)amine in rats.
    Mol Carcinog, 46(10): 819-23. [Abstract] [Full-text]
53. Overexpression of 14-3-3gamma causes polyploidization in H322 lung cancer cells.
    Mol Carcinog, 46(10): 847-56. [Abstract] [Full-text]
54. Microsatellite and EGFR, HER2 and K-RAS analyses in sclerosing hemangioma of the lung.
    Am J Surg Pathol, 31(10): 1512-20. [Abstract] [Full-text]
55. CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation.
    Nat Clin Pract Oncol, 4(10): 603-7. [Abstract] [Full-text]
56. International comparisons of survival from lung cancer: pitfalls and warnings.
    Nat Clin Pract Oncol, 4(10): 570-7. [Abstract] [Full-text]
57. Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors.
    Mol Immunol, 45(1): 169-79. [Abstract] [Full-text]

© 2004-2008 Lung Cancer Research Today. All Rights Reserved.